FDA Fluoroquinolone Warning Including Use for UTI Management
The FDA has issued warnings and updated drug safety information for oral and injectable fluoroquinolone antibiotics. ACOG has likewise released a practice advisory (November 2019) to help reinforce awareness regarding the use of these medications due to their role in the treatment of UTIs. The FDA recommends
Health care professionals should not prescribe systemic fluoroquinolones to patients who have other treatment options for acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic bronchitis (ABECB), and uncomplicated urinary tract infections (UTI) because the risks outweigh the benefits in these patients. Stop fluoroquinolone treatment immediately if a patient reports serious side effects, and switch to a non-fluoroquinolone antibacterial drug to complete the patient’s treatment course
Serious Fluoroquinolone Side Effects
Musculoskeletal and Peripheral Nervous System
Numbness or tingling or pricking sensation “pins
and needles” in arms or legs
Other Body Systems
Worsening of myasthenia gravis
Abnormal, rapid or strong heart beat
Central Nervous System
Additional FDA information for healthcare
Reserve use of fluoroquinolones for patients
with acute bacterial sinusitis (ABS), acute bacterial exacerbation of chronic
bronchitis (ABECB), and UTI, but no alternative therapies
Boxed Warning, Warnings and Precautions sections
of the labels and revised patient Medication Guide now describe serious risk of
multiple disabling and potentially irreversible adverse reactions that can
Discontinue the fluoroquinolone medicine
immediately at the first signs or symptoms of any serious adverse reaction (see
Note: The FDA
released a safety announcement (December 2018) regarding increased rare event
related to increased risk for aortic rupture or tears
OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Jointly provided by
NOT ENOUGH CME HOURS
It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan